{"id":"W4386021597","doi":"10.1097/01.hs9.0000968124.64352.6e","title":"S303: A PHASE 3 STUDY (ATLAS-PPX) TO EVALUATE EFFICACY AND SAFETY OF FITUSIRAN IN PEOPLE WITH HAEMOPHILIA A OR B WHO HAVE SWITCHED FROM PRIOR CLOTTING FACTOR CONCENTRATE OR BYPASSING AGENT PROPHYLAXIS","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Hemophilia Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sanofi (Canada)","funders":"","keywords":"Medicine; Tolerability; Haemophilia; Haemophilia B; Adverse effect; Clotting factor; Haemophilia A; Clinical endpoint; Internal medicine; Surgery; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001585998,0.0009506358,0.00135452,0.0002746863,0.0004708765,0.0008509097,0.0005962359,0.001402561,0.0140771],"category_scores_gemma":[0.0008460722,0.0003541898,0.001410316,0.000312178,0.0006294439,0.0007516738,0.0003802576,0.002267778,0.00197488],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005822518,"about_ca_system_score_gemma":0.001448308,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009249701,"about_ca_topic_score_gemma":0.003221415,"domain_scores_codex":[0.9996378,0.0001808402,0.00001944829,0.0000629231,0.0000475132,0.00005142245],"domain_scores_gemma":[0.9995763,0.00007273063,0.00008772536,0.00004031887,0.00005443445,0.0001684712],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7819272,0.04602687,0.007861607,0.002496033,0.002078245,0.0003719085,0.0004088993,0.001226234,0.03863643,0.0007784809,0.01403719,0.1041509],"study_design_scores_gemma":[0.718067,0.2544697,0.01604398,0.0001176488,0.0006368166,0.0004332244,0.00008072026,0.0008115068,0.001800732,0.0003756285,0.007123294,0.00003979256],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.968136,0.004204526,0.00135336,0.001051555,0.000231774,0.009291086,0.008713019,0.000365402,0.006653333],"genre_scores_gemma":[0.9567177,0.003128561,0.004953651,0.003279453,0.0002426198,0.01315085,0.009419384,0.00008498679,0.009022931],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0140771,"threshold_uncertainty_score":0.04709256,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06836513171879907,"score_gpt":0.3728361111625864,"score_spread":0.3044709794437873,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}